Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
As phase 3 trials progress, retatrutide could redefine metabolic pharmacotherapy, offering hope for millions battling obesity and T2D
PMID 10469335
It is available to a wider range of individuals (BMI 21+) and combines a tailored microdose of GLP-1 medication with regular advanced biomarker testing
That price tag is exactly why Medicaid coverage and the limits on it matter so much
Enrollment, follow-up, data analysis, NDA (New Drug Application) preparation, and FDA review typically add up to 18-36 months even with Breakthrough Therapy Designation, which Lilly has received for retatrutide in obesity
US$ 25.90
US$ 24.44
US$ 25.13
US$ 27.82
